Allergan has opened an EUR 160 million ($176 million) biologics facility at its Westport Campus in County Mayo, Ireland. The new facility will act as a global hub for Allergan’s flagship products, including Botox (onabotulinumtoxinA), one of its top-selling products with 2018 global sales of $2.5 billion.

The new facility, the Biologics 2 facility, features new manufacturing suites to meet growing global demand for Allergan’s products and features a new microbiology and cell-based laboratory with new technology and research and development capabilities to support discovery, development and manufacturing.  The new facility creates 63 new jobs.

Coinciding with the opening of the Biologics 2 facility, Allergan recently marked the shipping of the 100 millionth vial of Botox from the Westport campus as Allergan marked 30 years since the product first received FDA approval.

Allergan is headquartered in Ireland and operates four facilities—two manufacturing operations, one at Clonshaugh, Dublin and one in Westport, Co. Mayo—as well as an international supply-chain office in Earlsfort Terrace, Dublin, Ireland and a facility in Galway, Ireland following the 2017 acquisition of Zeltiq, which specializes in proprietary controlled-cooling technology for non-invasive fat reduction.  The Westport and Clonshaugh facilities develop and manufacture a range of branded medicines primarily for the export market. 

The new biologics facility brings Allergan’s total investment in Ireland since it began operations in the country to more than EUR 750 million ($825 million).

Source: IDA Ireland